Pharmacy Grand Rounds

To Taper or Not to Taper Opioids: Is That the Only Question?

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)
MN-RO-AL-MN-459-MAYO LH

Interactive Video Conference Room(s): 
MN-RO-GO-19-101 BARRETTE LH

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

With the recent recommendations and guidelines from public health and government organizations, clinicians are recommended to reduce the use of opioids in their population. However, chronic pain patients who have been maintained on opioids for years present a unique challenge. There is limited guidance from these documents on how to manage these chronic pain patients in light of this shift in prescribing culture. This presentation will target some of the common questions for opioid tapering such as the indications to consider opioid tapering, different tapering strategies, as well as additional factors to consider to increase chances of a successful taper.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Identify indications to consider opioid tapering in chronic pain patients
2. Compare potential opioid tapering strategies for patients with chronic pain using a patient case
3. Describe considerations for successful opioid tapering

Session Announcement

Session Slides

FACULTY INFORMATION

Linda L. Huang, PharmD
PGY2 Abulatory Care Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Linda received a Doctor of Pharmacy degree from University of Pittsburgh in Pittsburgh, PA with subsequent completion of PGY1 training at Temple University Hospital in Philadelphia, PA.  She is a current PGY2 Ambulatory Care Pharmacy Resident at Mayo Clinic - Rochester with practice interests in primary care and transitions of care.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Linda L. Huang, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Baclofen
    • Clonidine
    • Dicyclomine
    • Gabapentin
    • Tizanidine

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS